How to prevent progression to end stage renal disease

Journal of Renal Care

Volumn 33, Issue 3, 2007, Pages 105-107

  Riegersperger, Markus ^a   Sunder Plassmann, Gere ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chronic kidney disease; End stage renal disease; Progression

Indexed keywords

EID: 34548203107     PISSN: 1019083X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1755-6686.2007.tb00053.x     Document Type: Article

References (18)

1. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005 (98):S7-S10.
2. K/DOQI. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification. Am J Kidney Dis 2002; 39(suppl 1):S1-S000.
3. Campbell RC, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol 2002; 13 Suppl 3:S190-5.
4. Eckardt KU. Managing a fateful alliance: anaemia and cardiovascular outcomes. Nephrol Dial Transplant 2005;20 Suppl 6:vi16-20.
5. Grassmann A, Gioberge S, Moeller S, Brown G. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005; 20(12):2587-93.
6. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 2003; 14(7 Suppl 2):S65-70.
7. Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000; 11(2):319-29.
8. Orth SR, Stockmann A, Conradt C, Ritz E, Ferro M, Kreusser W, et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54(3):926-31.
9. McLaughlin JK, Lipworth L, Chow WH, Blot WJ. Analgesic use and chronic renal failure: a critical review of the epidemiologic literature. Kidney Int 1998; 54(3):679-86.
10. Li PK, Weening JJ, Dirks J, Lui SL, Szeto CC, Tang S, et al. A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney Int Suppl 2005 (94):S2-7.
11. Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353(9156):883-7.
12. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334(15):939-45.
13. Fioretto P, Solini A. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol 2005; 16 Suppl 1:S18-21.
14. Chiurchiu C, Remuzzi G, Ruggenenti P. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 2005; 16 Suppl 1:S58-63.
15. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14(4):992-9.
16. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361(9352):117-24.
17. Bakris GL, Williams M, Dworkin L, Elliot WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36(3):646-61.
18. Khan SS, Xue JL, Kazmi WH, Gilbertson DT, Obrador GT, Pereira BJ, et al. Does predialysis nephrology care influence patient survival after initiation of dialysis? Kidney Int 2005; 67(3):1038-46.